Collaboration and Knowledge Sharing: The biotech and pharma landscapes are constantly evolving, and in 2023, we’ve seen change accelerated by AI, digital and data technologies, regulation, and diversity and inclusion. In the face of these changes, clinical research leans on core processes like vendor selection, branding, and marketing, which need to be efficient and effective.

This year, we have supported a multitude of clients as they navigate these changing landscapes with their studies. We work shoulder-to-shoulder with their teams, to solve complex business challenges.

Collaboration is central to the way we work at Seuss+, and an important part of this is sharing our knowledge and expertise. In 2023, we broadened our reach by sharing our own and others’ insights through our podcast, email courses, and webinars.

In this blog post, I share snapshots of the highlights, giving you a head start on tackling challenges in 2024.

Cutting the Chat to Get to the Bottom of Big Biotech Issues

This year saw the launch of our Cut the Chat podcast, in which we talk with industry experts about some of the biggest topics biotech companies are dealing with.

We kicked off season 1 in June, when Seuss+ Co-Founder Sabine Hutchison spoke to industry leader Alan Morgan about measuring what truly matters in clinical trials. Listen to Episode 1 Smart KPIs for Biotechs to hear their conversation.

We continued in August, with Episode 2 Innovation Unleashed: Exploring the Intersection of Science and Creativity – An Unconventional Growth Strategy focusing on the boundless possibilities that emerge when science and creativity intertwine. Sabine had an inspiring conversation with guest Dr. Jennifer Buell – Chairman, Executive Council at Agenus and the President and CEO at MiNK Therapeutics.

Episode 3 – Cracking the code: Navigating the Ever-Changing Biotech Landscape took a step toward problem solving in September. Sabine spoke to Dr Allison Jeynes-Ellis, CEO of Avillion LLP, to tackle four hurdles that biotech companies encounter in their pursuit of innovation and life-changing breakthroughs.

In October’s Episode 4 – Cross-Pollination and Embedding DEI Strategies within Biotechs, Sabine had a thought-provoking conversation with Ben Osborn, President of the Europe Eastern Cluster at IDM, Pfizer, about the dynamic interplay of diversity, equity, and inclusion (DE&I) within the pharmaceutical and biotech sectors.

We finished the year with Viviënne van de Walle, a highly respected principal investigator, who spoke with Sabine about the challenges, triumphs, and patient-centric innovations in the dynamic world of biotech and clinical research in Episode 5 – Mastering the Art of Collaboration: Principal Investigator and Biotech Dynamics. 

We’d like to thank all our guests for sharing their insights and expertise this year. We launched the podcast to Cut the Chat and get to the heart of many life science and biotech conversations that need to happen for our industry to evolve, innovate, and get smarter—faster. The experts who have joined Sabine have been invaluable in achieving this aim.

The next episode is already in the works, and we’re looking forward to plenty of enlightening discussions in 2024. You can find us wherever you listen to your podcasts, and right here on our website.

Collaboration and Knowledge Sharing To Boost Biotech

Navigating the Perfect Storm: How biotechs can make informed decisions about switching CROs helps biotech organizations that are facing the complex decision of transitioning CRO services to make informed decisions and navigate this challenging process confidently.

Applying Our Insights to Help Solve Industry Issues

We also continued to share our insights virtually through webinars, following the impact they had in 2022.

At Seuss+, we have been working with clients on vendor selection for many years, so we know the mistakes that are often made and the best path to success. In the webinar A Systematic Framework for CRO Selection for Biotechs, Seuss+ CEO Kieran Canisius shares best practices and the process we have developed to help companies select the best-fit CRO.

Connecting, Collaborating, and Creating

People are at the heart of our collaborative approach, and it’s thanks to the experts who lead Seuss+ that we were able to make such a broad impact in 2023. Have you met our leadership team yet?

• Sabine Hutchison (CEO and Co-Founder) effortlessly sparks engaging and productive conversations, armed with her exceptional listening skills, sharp questioning, and insatiable curiosity
• Kieran Canisius (CEO and Co-Founder) firmly believes that, whether within organizations or relationships, ignoring challenging topics is not just unproductive but a major roadblock to progress.
• Hellen Boering (Director of Operations) – while Hellen’s early years in the Netherlands were marked by a strong affinity for sports, her academic pursuits and professional journey have been equally influential.
• Gina Dunn (Director of Marketing) knew from an early age that she wanted to be in the driver’s seat of her life and career; her journey is a testament to her resilience, determination, and passion for learning.
• Susan Braakman (Director of Group Services) – Susan’s career milestones, including her role as Business Director for DOCS, reinforce her core belief that businesses should prioritize their people.

Looking Forward to a Successful 2024

Looking back at 2023, we are proud of the impact we’ve made and grateful to all those who collaborated with us to support biotech and pharma leaders around the world.

We’re looking forward to more cooperation in 2024, and to continuing our deep-dive conversations and insightful knowledge-sharing efforts. If you’d like to hear about the latest news, you can sign up to our newsletter and follow us on LinkedIn.

From all of us at Seuss+, we hope you have a very happy Christmas and an inspiring, energetic, and successful New Year!